Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02917031 · ClinicalTrials.gov registry record · Phase 4
Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 348
- Enrollment target
NCT02917031: Completed Phase 4 study, sponsored by AstraZeneca.
NCT02917031 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 348 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02917031, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 348 participants
- Enrollment target
Study Summary
This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).
Primary Outcome
MRI was performed to evaluate LVEDV at baseline and Visit 10 (Week 24). Evaluated to exclude an increase in left ventricular end diastolic volume (LVEDV) index of greater than 10% of the overall baseline value (noninferiority margin) in patients with T2DM and HF treated with saxagliptin for 24 weeks, compared to placebo. Baseline is last assessment on or before the date of first dose.
Interventions
- DRUG Sitagliptin
- DRUG Saxagliptin
- DRUG Placebo to match saxagliptin
- DRUG Placebo to match sitagliptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2017-01-10 |
| Est. Completion | 2019-08-23 |
| Phase | Phase 4 |
What the finished NCT02917031 record still lists
NCT02917031 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 4 interventions - of which Sitagliptin is the first listed.
NCT02917031 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02917031 about?
NCT02917031 is a clinical study titled "Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure". This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).
What is the current status of trial NCT02917031?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 348 participants. The study started on 2017-01-10. Estimated completion is 2019-08-23.
What interventions are being tested in trial NCT02917031?
The interventions under investigation include: Sitagliptin (DRUG), Saxagliptin (DRUG), Placebo to match saxagliptin (DRUG), Placebo to match sitagliptin (DRUG).
Who is sponsoring clinical trial NCT02917031?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02917031's enrollment target sits among peer trials
348 240th of 2000 higher than 1,760 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI